| Ex vivo human adipose tissue derived mesenchymal stromal cells (ASC) are a heterogeneous population that demonstrate rapid culture-induced changes AES Brooks, M Iminitoff, E Williams, T Damani, V Jackson-Patel, V Fan, ... Frontiers in pharmacology 10, 1695, 2020 | 36 | 2020 |
| Selectively Targeting Tumor Hypoxia with the Hypoxia-Activated Prodrug CP-506 AMA van der Wiel, V Jackson-Patel, R Niemans, A Yaromina, E Liu, ... | 27 | 2021 |
| Visualization and quantification of mesenchymal cell adipogenic differentiation potential with a lineage specific marker J Eom, V Feisst, L Ranjard, K Loomes, T Damani, V Jackson-Patel, ... JoVE (Journal of Visualized Experiments), e57153, 2018 | 16 | 2018 |
| Structure of AKR1C3 with 3-phenoxybenzoic acid bound VJ Jackson, Y Yosaatmadja, JU Flanagan, CJ Squire Acta Crystallographica Section F: Structural Biology and Crystallization …, 2012 | 14 | 2012 |
| Abstract A67: Preclinical efficacy of tarloxotinib bromide (TH-4000), a hypoxia-activated EGFR/HER2 inhibitor: rationale for clinical evaluation in EGFR mutant, T790M-negative … S Silva, V Jackson, C Guise, M Abbattista, M Bull, A Grey, R Anderson, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), A67-A67, 2015 | 7 | 2015 |
| Tissue pharmacokinetic properties and bystander potential of hypoxia-activated prodrug cp-506 by agent-based modelling V Jackson-Patel, E Liu, MR Bull, A Ashoorzadeh, G Bogle, A Wolfram, ... Frontiers in Pharmacology 13, 38, 2022 | 6 | 2022 |
| Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3 MR Abbattista, A Ashoorzadeh, CP Guise, AM Mowday, R Mittra, S Silva, ... Pharmaceuticals 14 (12), 1231, 2021 | 5 | 2021 |
| Hypoxia tumour targeting with tarloxotinib to improve clinical outcomes for patients with EGFR‐dependent malignancies V Jackson‐Patel, K Hicks, S Silva, C Guise, M Bull, M Abbatista 5th International Conference on Tumour Microenvironment and Cellular Stress …, 2018 | 3 | 2018 |
| Abstract A66: Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell … V Jackson, S Silva, M Abbattista, C Guise, M Bull, A Ashoorzadeh, C Hart, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), A66-A66, 2015 | 3 | 2015 |
| Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the … V Jackson, S Silva, M Abbattista, C Guise, M Bull, A Ashoorzadeh, C Hart, ... AACR-NCI-EORTC International Conference on Molecular Targets and Cancer …, 2015 | 2 | 2015 |
| Kinase inhibitor prodrug for the treatment of cancer AV Patterson, JB Smaill, S Silva, CP Guise, MR Bull, V Jackson, T Pearce, ... US Patent 10,507,210, 2019 | 1 | 2019 |
| Inhibiting the Epidermal Growth Factor Receptor (EGFR) to improve clinical outcomes for patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) VJ Jackson-Patel PhD Thesis-University of Auckland, 2018 | 1 | 2018 |
| Development of biomarkers to guide the clinical development of tarloxotinib bromide, a hypoxia-activated irreversible EGFR/HER2 inhibitor. AV Patterson, RJ Kimple, VJ Jackson, AD Swick, CP Guise, MR Abbattista, ... Journal of Clinical Oncology 34 (15_suppl), e17521-e17521, 2016 | 1 | 2016 |
| Kinase inhibitor prodrug for the treatment of cancer AV Patterson, JB Smaill, S SILVA, CP Guise, MR BULL, V JACKSON, ... | | 2016 |
| The Hypoxia-Activated EGFR-TKI TH-4000: Preclinical Profile and Ongoing Clinical Studies in NSCLC, SCCHN, and SCCS A Patterson, S Silva, V Jackson, C Guise, M Abbattista, M Bull, A Hsu, ... 14th International Tumor Microenvironment Workshop: Hypoxia, Angiogensis and …, 2015 | | 2015 |
